Mhc class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma

被引:97
作者
Atkins, D
Breuckmann, A
Schmahl, GE
Binner, P
Ferrone, S
Krummenauer, F
Strökel, S
Seliger, B
机构
[1] Johannes Gutenberg Univ Mainz, Dept Internal Med 3, D-6500 Mainz, Germany
[2] Univ Witten Herdecke, Inst Pathol, Wuppertal, Germany
[3] Univ Witten Herdecke, Int Mol & Clin Cardiovasc Res, Dortmund, Germany
[4] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA
[5] Johannes Gutenberg Univ Mainz, Dept Med Biometry Epidemiol & Informat, D-6500 Mainz, Germany
关键词
ras; MHC; colorectal cancer; antigen processing;
D O I
10.1002/ijc.11681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal tumorigenesis has been associated with the progressive acquisition of a variety of genetic alterations. These include mutations of the Ki-ras proto-oncogene in codons 12 and 13, which account for 85% of genetic changes in colorectal cancer. In murine in vitro models of oncogenic transformation, an association between ras-mediated transformation and downregulation of different components of the MHC class 1 antigen processing machinery (APM) has been described. In order to investigate whether this association also exists in human tumors, 10 cases of high-grade intraepithelial neoplasia (HIN), as well as primary tumors and autologous lymph node metastases from 42 patients with colorectal carcinoma, were monitored by allele-specific restriction analysis for Ki-ras mutations. In parallel, APM component expression and tumor cell proliferation were analyzed by immunohistochemistry. In comparison to autologous colorectal mucosa, TAP1, LMP2 and tapasin loss was found in 68%, 67% and 80% of HIN, respectively. In contrast, impaired TAPI, LMP2 and tapasin expression was found in 42%, 42% and 63% of primary adenocarcinomas of stage III disease and in 63%, 47% and 79% of the matched lymph node metastases, respectively. More than 60% of colorectal tumor lesions with TAP1, LMP2 and/or tapasin defects displayed Ki-ras mutations. The frequency of TAP I, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases. These data suggest that i) APM component deficiencies occur more frequently in Ki-ras-mutated colorectal carcinoma lesions and ii) APM abnormalities in conjunction with Ki-ras mutations appear to be associated with disease stage. These findings support the hypothesis that Ki-ras mutations may contribute to immune escape mechanisms of tumors by downregulating the MHC class 1 APM component expression. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:265 / 273
页数:9
相关论文
共 55 条
[1]   Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations [J].
Abrams, SI ;
Khleif, SN ;
Bergmann-Leitner, ES ;
Kantor, JA ;
Chung, Y ;
Hamilton, JM ;
Schlom, J .
CELLULAR IMMUNOLOGY, 1997, 182 (02) :137-151
[2]   Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4(+) and CD8(+)T cell responses [J].
Abrams, SI ;
Stanziale, SF ;
Lunin, SD ;
Zaremba, S ;
Schlom, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (02) :435-443
[3]   TAP expression provides a general method for improving the recognition of malignant cells in vivo [J].
Alimonti, J ;
Zhang, QJ ;
Gabathuler, R ;
Reid, G ;
Chen, SS ;
Jefferies, WA .
NATURE BIOTECHNOLOGY, 2000, 18 (05) :515-520
[4]   Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, JR ;
Clarke, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684
[5]  
Ashrafi GH, 2002, ONCOGENE, V21, P248
[6]   Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides [J].
Benitez, R ;
Godelaine, D ;
Lopez-Nevot, MA ;
Brasseur, F ;
Jiménez, P ;
Marchand, M ;
Oliva, MR ;
van Baren, N ;
Cabrera, T ;
Andry, G ;
Landry, C ;
Ruiz-Cabello, F ;
Boon, T ;
Garrido, F .
TISSUE ANTIGENS, 1998, 52 (06) :520-529
[7]  
Bristol JA, 1998, J IMMUNOL, V160, P2433
[8]   Mechanisms of loss of HLA class I expression on colorectal tumor cells [J].
Browning, M ;
Petronzelli, F ;
Bicknell, D ;
Krausa, P ;
Rowan, A ;
Tonks, S ;
Murray, N ;
Bodmer, J ;
Bodmer, W .
TISSUE ANTIGENS, 1996, 47 (05) :364-371
[9]   Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways:: β2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors [J].
Cabrera, CM ;
Jiménez, P ;
Cabrera, T ;
Esparza, C ;
Ruiz-Cabello, F ;
Garrido, F .
TISSUE ANTIGENS, 2003, 61 (03) :211-219
[10]   High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas [J].
Cabrera, T ;
Collado, A ;
Fernandez, MA ;
Ferron, A ;
Sancho, J ;
Ruiz-Cabello, F ;
Garrido, F .
TISSUE ANTIGENS, 1998, 52 (02) :114-123